Sars-Cov-2 pandemic and PRRT: The experience of European Institute of Oncology (IEO), Milano, Italy

#3357

Introduction: The importance of timely assistance in oncological patients is undeniable; however it is well known that these patients could have important clinical problems if they were infected by COVID-19, with an increased risk of severe illness and mortality. A recent multicenter Italian study reported a delay both in the beginning of PRRT for new patients and in those ones who had already started the treatment, as a direct consequence of COVID-19.

Aim(s): The aim of this study was to understand if SARS-CoV2 infection has modified our clinical management, with particular attention to PRRT.

Materials and methods: The weekly multidisciplinary tumor board never stopped during the pandemic. In those months, pts were treated with PRRT in the same way of previous years, remaining one night in Radiometabolic Therapy Unit, receiving a PCR test the day before the treatment. We made a comparison between the number of PRRT cycles (either in clinical practice or in clinical trials) performed at IEO from February 2020 to July 2021, with those performed in the previous year (February 2019-January 2020).

Conference:

Presenting Author: Grana C

Authors: Grana C, Fazio N, Spada F, Rocca P, Laffi A,

Keywords: PRRT, GEP-NET, COVID-19,